1) G-BA considers German guidelines where available.
2) The therapeutic field with the highest proportion of G-BA considering exclusively non-German guidelines is eye diseases.
3) G-BA's main reasons for considering no guidelines are orphan designations and failure to identify relevant guidelines, possibly due to low disease incidence/ prevalence.
Key findings
Of 137 relevant assessments, the G-BA referred to German guidelines in 42% of cases when determining the appropriate comparator for early benefit assessment, while in 31% exclusively non-German guidelines were considered. For the following therapeutic areas, this was the case in >50% for eye diseases (80%), diseases of respiratory system (63%), cardiovascular diseases (60%), and diseases of blood and blood forming organs (60%). In 27%, the G-BA referred to no guidelines at all. Of these, 24% corresponded to pharmaceuticals with orphan drug designation and one diagnostic tool, while 3% corresponded to regular pharmaceuticals. In oncology, making up for 40% of the submitted dossiers, a similar trend as in the main analysis was observed with reference of the G-BA to German guidelines in 47% of cases, while in 24% exclusively non-German guidelines were considered. G-BA's main reason to not consider any guidelines for regular pharmaceuticals was that no relevant guidelines were detected during the systematic guideline search. This might be due to low incidence/prevalence diseases in combination with very narrow drug indications. 
